2006
Quantitative in Situ Assessment of the Somatostatin Receptor in Breast Cancer to Assess Response to Targeted Therapy With 111-in-Penetreotide
Chung G, Murren J, Rimm D. Quantitative in Situ Assessment of the Somatostatin Receptor in Breast Cancer to Assess Response to Targeted Therapy With 111-in-Penetreotide. 2006 DOI: 10.21236/ada455786.Peer-Reviewed Original ResearchBreast cancerTissue microarrayPredominant receptor subtypeBenign breast tissueSSTR2 levelsProgression of cancerSSTR2 expressionBone tumorsTargeted therapyReceptor subtypesSomatostatin receptorsClinical significanceCo-localization techniquesCell line controlMalignant cellsCancerBreast tissuePattern of expressionProtein expressionPeptide hormonesSomatostatinSSTR2ExpressionLarge proportionTherapy
2005
Quantitative in Situ Assessment of the Somatostatin Receptor in Breast Cancer to Assess Response to Targeted Therapy with 111-In-Pentetreotide
Chung G, Murren J, Rimm D. Quantitative in Situ Assessment of the Somatostatin Receptor in Breast Cancer to Assess Response to Targeted Therapy with 111-In-Pentetreotide. 2005 DOI: 10.21236/ada436873.Peer-Reviewed Original ResearchBreast cancerTissue microarraySSTR2 expressionClinical trialsPredominant receptor subtypeRadiolabelled SST analoguesMetastatic breast cancerRadiolabelled somatostatin analoguesMalignant breast epitheliumResponse/survivalBenign breast tissueCell lines expressionProgression of cancerSST analogsSomatostatin analoguesTargeted therapyReceptor subtypesSomatostatin receptorsBreast epitheliumCo-localization techniquesCancerBreast tissueSSTR2Protein expressionPeptide hormones